Author:
Bublin Merima,Kostadinova Maria,Radauer Christian,Varga Eva-Maria,Hafner Christine,Schmidthaler Klara,Saidova Aziza,Maleki Soheila J.,Szépfalusi Zsolt,Eiwegger Thomas,Breiteneder Heimo
Funder
Austrian Research Promotion Agency
Medical Scientific Fund
Hospital for Sick Children
Innovation Fund
Aimmune Therapeutics
DBV
Subject
Immunology,Immunology and Allergy
Reference21 articles.
1. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial;Bird;J Allergy Clin Immunol Pract,2018
2. An unfolded variant of the major peanut allergen Ara h 2 with decreased anaphylactic potential;Starkl;Clin Exp Allergy,2012
3. Chemical modification of peanut conglutin reduces IgE reactivity but not T cell reactivity in peanut-allergic patients;van Hoffen;Clin Exp Allergy,2014
4. Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy;Bannon;Int Arch Allergy Immunol,2001
5. A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy;Wood;Allergy,2013
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献